Array BioPharma, Inc.
) recently presented data on ARRY-520 from two ongoing studies in
In 2012, Array BioPharma made progress on its proprietary
programs ARRY-614 (indicated for myelodysplastic syndromes) and
ARRY-520 (indicated for MM). Array BioPharma wants to invest its
resources in the hematology/oncology segment, in which it sees
great opportunities. This year, Array BioPharma expects to
generate more data for registration of study decisions of the two
Single agent activity was demonstrated by ARRY-520 in
pretreated patients - median overall survival and overall
response rate was 19 months and 16%, respectively.
In the study, ARRY-520 was well tolerated. Predominant adverse
events like transient and non-cumulative neutropenia and
thrombocytopenia were manageable. There was a low-incidence of
non-hematologic adverse events and no-treatment related
neuropathy was observed.
In the second study, ARRY-520 was evaluated in combination
) Velcade (bortezomib). The combination was well-tolerated. The
most common adverse event was neutropenia.
Initial response and prolonged stable disease was observed in
the patient population, most of whom had not benefitted from
Velcade treatment. The study will also evaluate an alternate
treatment regimen with the addition of low-dose
We note companies like
Onyx Pharmaceuticals, Inc.
) have a presence in the multiple myeloma market. Onyx
Pharmaceuticals' Kyprolis (carfilzomib) is indicated for the
treatment of multiple myeloma patients who have received at least
two prior therapies including Velcade and an immunomodulatory
agent, and whose disease has progressed on or within 60 days of
completion of the last therapy.
Currently, Array BioPharma carries a Zacks Rank #3 (Hold).
However, companies like
) look better positioned with a Zacks Rank #2 (Buy).
ARRAY BIOPHARMA (ARRY): Free Stock Analysis
GTX INC (GTXI): Free Stock Analysis Report
ONYX PHARMA INC (ONXX): Free Stock Analysis
TAKEDA PHARMACT (TKPYY): Get Free Report
To read this article on Zacks.com click here.